Yes, Wegovy Pills Exist — Here Is What You Need to Know

What the approval actually means for someone considering oral semaglutide

The approval on 11 June 2026 settled a question that had been circulating for years in weight-management circles: could a GLP-1 medicine work as a tablet? The answer, at least for semaglutide, is yes. The Wegovy tablet uses an absorption enhancer called SNAC to help semaglutide cross the stomach lining, a formulation challenge that had stalled earlier attempts at oral GLP-1 medicines.

The licensed population mirrors the injection closely: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure or high cholesterol, used alongside a reduced-calorie diet and increased activity. It is not available on the NHS yet (a NICE appraisal would be needed first) so at launch it is a private prescription only. You can read more about how the Wegovy tablet works and who it suits in our dedicated guide.

The OASIS 4 phase 3 trial, which underpinned the MHRA's decision, ran for 64 weeks and enrolled 307 adults with obesity or overweight plus at least one weight-related condition. Average weight loss was around 13.6% with the tablet versus around 2.4% with placebo. Among those who stayed fully adherent throughout the trial, that figure rose to roughly 16.6%, a meaningful distinction worth keeping in mind when comparing headline numbers. The OASIS 4 trial results in full are covered separately if you want the deeper detail.

The practical differences between the tablet and the injection

For many people the decision is less about clinical outcomes and more about daily practicalities. The injection pen goes in the fridge; the tablet sits on the bathroom shelf. If you travel regularly, share a fridge, or simply find the idea of a weekly injection off-putting, those details matter.

The tablet is taken first thing in the morning, before anything else, food, coffee, other medicines. You swallow it whole with a small amount of plain water (up to around 120 ml) and then wait at least 30 minutes before eating or drinking anything else. It is a deliberate routine rather than an afterthought, which suits some people well and feels constraining to others. One quick check worth doing: look at your existing morning routine and ask honestly whether that 30-minute gap is reliably achievable on the days you are busiest. That single question tells you a lot about whether the tablet or the injection is the better fit for your lifestyle.

The injection, by contrast, is weekly rather than daily, which removes the daily-routine dependency. Both forms carry the same GLP-1 side-effect profile (predominantly gastrointestinal in the early weeks) and both require a prescriber's assessment before starting. More on semaglutide tablets versus the injection is available if you want a side-by-side breakdown.

Side effects to be aware of before you decide

The most common effects with the tablet in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported by around 74% of participants on the active tablet compared with 42% on placebo. That is a notable difference, though most effects were described as mild to moderate and tended to settle as the body adjusted to each dose level. The titration schedule (at least one month at each step before moving up) exists precisely to give your system time to adapt.

Persistent, severe stomach pain that spreads towards the back warrants prompt medical attention; the MHRA has highlighted acute pancreatitis as an infrequent but serious consideration for GLP-1 medicines. Any side effect you are uncertain about can be reported directly to the MHRA via the Yellow Card scheme. Pregnancy, breastfeeding, and actively trying to conceive are circumstances in which Wegovy tablets are not recommended; the same applies to anyone under 18. These are conversations for a prescriber, not a checklist to self-assess.

If you have been wondering whether there is a pill version of Wegovy and how it compares to the injection, the semaglutide pill overview covers both the weight-management and diabetes-licensed forms clearly, including how Wegovy tablets differ from Rybelsus. For anyone still asking whether a Wegovy pill actually exists, that guide also explains what the 2026 approval means in practical terms, and if you want a concise answer to whether Wegovy comes in pill form, that page sets out exactly what the licensed tablet option involves.

Getting a prescription: what the process looks like at a regulated pharmacy

Wegovy tablets are a prescription-only medicine. The only legal route to them in the UK is through a clinical assessment with a qualified prescriber, there is no shortcut that a legitimate pharmacy would offer. At nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber. Your answers are read by a real clinician, not processed by software.

If you are already established on the 2.4 mg Wegovy injection, it is worth knowing that the SmPC notes patients at that maintenance dose may be able to move directly to the 25 mg tablet, subject to clinical assessment. That transition is something to discuss openly during your consultation rather than assume. Our clinical team can advise on the right starting point for your situation.

You can also explore our weight-loss treatment overview to compare all currently available options before you decide. When you are ready, check your eligibility and one of our prescribers will review your consultation the same day.